Scholar Rock Holding (SRRK) Cash from Investing Activities (2017 - 2026)
Scholar Rock Holding's (SRRK) quarterly Cash from Investing Activities came in at -$5.3 million in Q1 2026, down 115.44% year-on-year from $34.6 million in Q1 2025, and down 113.69% quarter-over-quarter from $39.0 million in Q4 2025.
Scholar Rock Holding (SRRK) Cash from Investing Activities (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Cash from Investing Activities history runs 10 years deep, the most recent figure standing at -$5.3 million for Q1 2026.
- On a quarterly basis, Cash from Investing Activities fell 115.44% year-over-year to -$5.3 million in Q1 2026; TTM through Mar 2026 was $178.8 million, a 338.76% increase from a year earlier, with the FY2025 full-year figure at $218.7 million, up 387.53% from the prior year.
- Cash from Investing Activities retreated to -$5.3 million in Q1 2026 per SRRK's latest filing, from $39.0 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $90.0 million in Q1 2023 and bottomed at -$195.4 million in Q4 2024.
- The 5-year median for Cash from Investing Activities is $33.4 million (2024), against an average of $396411.8.
- Across the five-year window, Cash from Investing Activities tumbled 32733.77% in 2023 and jumped 516.71% in 2024, its largest moves.
- Year by year, Cash from Investing Activities stood at $77000.0 in 2022, then tumbled by 32733.77% to -$25.1 million in 2023, then plunged by 677.5% to -$195.4 million in 2024, then soared by 119.95% to $39.0 million in 2025, then plunged by 113.69% to -$5.3 million in 2026.
- Per Business Quant, the three latest SRRK Cash from Investing Activities figures stand at -$5.3 million (Q1 2026), $39.0 million (Q4 2025), and $59.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | Scholar Rock Holding | 6.32 Bn | 6.32 Bn | - | -5.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.34 Mn |
| Mar 31, 2026 | -5.34 Mn |
| Dec 31, 2025 | 38.97 Mn |
| Dec 31, 2025 | 38.97 Mn |
| Sep 30, 2025 | 59.70 Mn |
| Sep 30, 2025 | 59.70 Mn |
| Jun 30, 2025 | 85.47 Mn |
| Jun 30, 2025 | 85.47 Mn |
| Mar 31, 2025 | 34.55 Mn |
| Mar 31, 2025 | 34.55 Mn |
| Dec 31, 2024 | -195.37 Mn |
| Dec 31, 2024 | -195.37 Mn |
| Sep 30, 2024 | 35.31 Mn |
| Sep 30, 2024 | 35.31 Mn |
| Jun 30, 2024 | 50.62 Mn |
| Jun 30, 2024 | 50.62 Mn |
| Mar 31, 2024 | 33.38 Mn |
| Mar 31, 2024 | 33.38 Mn |
| Dec 31, 2023 | -25.13 Mn |
| Dec 31, 2023 | -25.13 Mn |